Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Rating) traded up 1.2% during mid-day trading on Monday . The stock traded as high as $4.28 and last traded at $4.20. 35,577 shares were traded during mid-day trading, an increase of 33% from the average session volume of 26,684 shares. The stock had previously closed at $4.15.
Enlivex Therapeutics Trading Up 1.2 %
The company’s fifty day simple moving average is $4.29 and its 200 day simple moving average is $4.54. The stock has a market capitalization of $77.33 million, a P/E ratio of -2.69 and a beta of 1.03.
Enlivex Therapeutics (NASDAQ:ENLV – Get Rating) last issued its quarterly earnings data on Monday, December 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Equities research analysts predict that Enlivex Therapeutics Ltd. will post -1.64 earnings per share for the current year.
Institutional Trading of Enlivex Therapeutics
Enlivex Therapeutics Company Profile
Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.
- Get a free copy of the StockNews.com research report on Enlivex Therapeutics (ENLV)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.